incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The spatial arrangement of the C-C and C-H bonds are described by the torsion angles of the molecule, known as its conformation. In ethane, the simplest case for studying the conformation of alkanes, there is nearly free rotation about a carbon–carbon single bond. Two limiting conformations are important: eclipsed conformation and staggered conformation. The staggered conformation is 12.6 kJ/mol (3.0 kcal/mol) lower in energy (more stable) than the eclipsed conformation (the least stable). In highly branched alkanes, the bond angle may differ from the optimal value (109.5°) to accommodate bulky groups. Such distortions introduce a tension in the molecule, known as steric hindrance or strain. Strain substantially increases reactivity.
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication. It was approved for medical use in the European Union in October 2005, and in the United States in September 2006. It is available as a generic medication.
Robert Allan Humphreys (1930–1988), known as Laud Humphreys, was an American sociologist and Episcopal priest. He is noted for his research into sexual encounters between men in public bathrooms, published as Tearoom Trade (1970), and for the questions that emerged regarding the ethical nature of his research methods. He influenced generations of scholars who research issues related to sexuality and sexual identity.
Murphree developing centrifuges, and Arthur Compton responsible for theoretical studies and design. On 23 April 1942, Met Lab scientists discussed seven possible ways to extract plutonium from irradiated uranium, and decided to pursue investigation of all seven. On 17 June, the first batch of uranium nitrate hexahydrate (UNH) was undergoing neutron bombardment in the Washington University in St. Louis cyclotron. On 27 July, the irradiated UNH was ready for Glenn T. Seaborg's team. On 20 August, using ultramicrochemistry techniques, they successfully extracted plutonium. In May 1942, Gertrude Scharff Goldhaber at Brookhaven National Laboratory reports for the first the emission of multiple neutrons during spontaneous fission of uranium. Her research was kept a secret. In April 1939, creating a chain reaction in natural uranium became the goal of Fermi and Szilard, as opposed to isotope separation. Their first efforts involved five hundred pounds of uranium oxide from the Eldorado Radium Corporation. Packed into fifty-two cans two inches in diameter and two feet long in a tank of manganese solution, they were able to confirm more neutrons were emitted than absorbed. However, the hydrogen within the water absorbed the slow neutrons necessary for fission. Carbon in the form of graphite, was then considered, because of its smaller capture cross section. In April 1940, Fermi was able to confirm carbon's potential for a slow-neutron chain reaction, after receiving National Carbon Company's graphite bricks at their Pupin Laboratories.
==== Other drugs ==== Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2A receptor antagonist [347] Pimavanserin (ACP-103; BVF-048; Nuplazid) – serotonin 5-HT2A receptor antagonist – Parkinson's disease psychosis [348]
Sources: en.wikipedia.org
=== Role in synchronized fertilization on dairy farms === By using cows that produce offspring within a one to two-week period, synchronized breeding allows dairy farmers to artificially inseminate cows for maximum pregnancy rates with minimal effort. BST is a placental lactogen (PL) hormone and falls under the class of growth hormone, or somatotropin. It is relevant to the practice of artificially expediting placental development in farm mammals, specifically dairy cattle. The mechanism through which the hormones of this somatotropin exert their effects can be observed at the cellular and molecular level in placental tissue. For mammals exposed to the hormone, bovine somatotropin associates with N-glycosylated proteins that are heavily involved in placental gestation. Knowledge of this and how BST works in conjunction with growth hormones allows for agricultural researchers to experiment on the effects of synchronization in farm animals. Synchronization involves treating cattle with a dose of BST before artificially inseminating them, according to a fixed interval schedule. Synchronization and BST treatment may be used to increase first-service pregnancy rates while following this timed artificial insemination protocol. This would therefore allow agricultural researchers to observe the effects of hormones in relation to natural estrous cycles. Dairy cattle experienced increased rates of pregnancy during synchronization when exposed to BST.
== History == It was formed in 1975, by the remnants of the Organization of Spanish Marxist-Leninists (OMLE) which was dissolved that year. OMLE, which was operating from exile, had been formed through a 1968 split in the Communist Party of Spain (PCE). Following the famous revolts in Paris in 1968, certain groups of leftist Spanish exiles were disappointed with the staunchly pro-Soviet and “frozen” stance of the Spanish Communist Party, the PCE and its leader Santiago Carrillo. This led in September of the same year to the foundation of the Organización de Marxistas Leninistas Españoles (OMLE) (Organization of Spanish Marxist-Leninists) in Brussels. In 1974 Organización Obreira, a Galician organization, joined the OMLE. During the following years, this splinter group of Spanish Communists was inspired by ETA’s rise and by the military coup in Portugal that led to the Carnation Revolution. Thus it accumulated a number of sympathizers and well-wishers, especially among left-wing circles in the Spanish youth. Franco’s illness was also interpreted as an omen for a wide-open future and a promise of success for the PCE(r)'s ambitions and goals. The OMLE renamed itself “Partido Comunista de España Reconstituido” in June 1975. Two months after Franco’s death, in January 1976, during the Spanish political transition from dictatorship to democracy, the PCE(r) began a "revolutionary struggle" against the political reforms of the newly established monarchy of King Juan Carlos I. In order to carry about its struggle, the PCE(r) restructured itself into different commissions.
== Disease relevance == Due to its involvement in a great number of signaling pathways, GSK-3 has been associated with a host of high-profile diseases. GSK-3 inhibitors are currently being tested for therapeutic effects in Alzheimer's disease, type 2 diabetes mellitus (T2DM), some forms of cancer, and bipolar disorder. There is evidence that lithium, which is used as a treatment for bipolar disorder, acts as a mood stabilizer by selectively inhibiting GSK-3. The mechanism through which GSK-3 inhibition may stabilize mood is not known, though it is suspected that the inhibition of GSK-3's ability to promote inflammation contributes to the therapeutic effect. Inhibition of GSK-3 also destabilises Rev-ErbA alpha transcriptional repressor, which has a significant role in the circadian clock. Elements of the circadian clock may be connected with predisposition to bipolar mood disorder. GSK-3 activity has been associated with both pathological features of Alzheimer's disease, namely the buildup of amyloid-β (Aβ) deposits and the formation of neurofibrillary tangles. GSK-3 is thought to directly promote Aβ production and to be tied to the process of the hyperphosphorylation of tau proteins, which leads to the tangles. Due to these roles of GSK-3 in promoting Alzheimer's disease, GSK-3 inhibitors may have positive therapeutic effects on Alzheimer's patients and are currently in the early stages of testing. In a similar fashion, targeted inhibition of GSK-3 may have therapeutic effects on certain kinds of cancer.
The three "PSL Forums" are now defunct, yet looksmaxxing spread beyond manosphere communities and entered broader online culture, gaining popularity on platforms such as TikTok during the early 2020s. In contrast to earlier discussions on message boards, which were more closely associated with the black pilled worldview, early TikTok content often framed looksmaxxing in terms of self-improvement, sometimes incorporating self-deprecating humor. However, by the mid 2020s, the black pill ideology became increasingly associated with the practice in mainstream discourse. Certain online influencers, such as Kick livestreamer Braden Peters, a.k.a. "Clavicular", have also been linked to the promotion of more extreme forms of looksmaxxing and black pill ideology.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.